“Simply stated, Mifepristone, as used in real-world conditions, is not ‘safe and effective,’” wrote the researchers, which consisted of a team of scientists, board-certified obstetricians and gynecologists, analysts, and engineers.
Described as the “largest-known study of the abortion pill,” the EPPC analyzed 865,727 Mifepristone abortions under “real-world conditions” from 2017 to 2023 using an “all-payer insurance claims database.” In contrast, the report notes, the FDA relies on decade-old data from 10 clinical trials that involved just 30,966 “pre-screened” and “generally healthy” women. Under that small data set, which found less than 0.5 percent of women suffered serious adverse reactions, the FDA lets Danco Laboratories market Mifepristone, under the label “Mifeprex,” as “safe and effective.” However, the EPPC examined data that is more “broadly representative” of the women actually having Mifepristone abortions in America rather than just relying on data from the “carefully controlled regimen of care” of a clinical trial. These women would have had varying degrees of real-world “pre- and post-abortion health care,” if any care at all.
“The real-world rate of serious adverse events following Mifepristone abortions is at least 22 times as high as the summary figure of ‘less than 0.5 percent’ in clinical trials reported on the drug label,” read the report. “10.93 percent of women experience sepsis, infection, hemorrhaging, or another serious or life-threatening adverse event within 45 days following a Mifepristone abortion.”
The specific rates of serious complications consisted of:
- abortion-related emergency room visit (4.73 percent)
- hemorrhage (3.31 percent)
- infection (1.34 percent)
- ectopic pregnancy (0.35 percent)
- abortion-related hospitalization (0.66 percent)
- transfusion (0.15 percent)
- sepsis (0.10 percent)
- unspecified other abortion-specific complications (5.68 percent),
- other life-threatening adverse events (0.22 percent), including cardiac and pulmonary events, thrombosis, anaphylaxis, and the necessity of surgery.
Notably, nearly three percent of the adverse events required a follow-on surgical abortion due the abortion drug failing.